US · Healthcare · Biotechnology
EPS came in at -0.38 against a street estimate of -0.36 — a miss of 5.6%.
Analysts rate Oric Pharmaceuticals Inc a strong buy (14 buy, 1 hold, 0 sell out of 15) with an average price target of $21.71.
| Fund | Stake |
|---|---|
| Nextech Invest, Ltd. | 6.91% |
| BlackRock Inc | 6.58% |
| EcoR1 Capital, LLC | 6.49% |
| T. Rowe Price Associates, Inc. | 6.38% |
| Viking Global Investors LP | 4.95% |
| State Street Corp | 4.72% |
| SR ONE CAPITAL MANAGEMENT, LP | 4.45% |
| VR Adviser, LLC | 4.17% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • ORIC Pharmaceuticals presented updated Phase 1b data for enozertinib (ORIC-114) in EGFR atypical and EGFR exon 20 insertion non-sm | 2026-10-23 |
| Quarterly report · Q2 2026 ORIC PHARMACEUTICALS, INC. – 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash and investments: $37.5 million cash + $227.3 million short-te | 2026-08-03 |
| Results announced · Q3 2026 ORIC PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and investments: $387.6 million as of June 30, 2026 • Runwa | 2026-08-03 |
| Board / officer change · Q3 2026 ORIC PHARMACEUTICALS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) • Filing Date: July 30, 2026 (reporti | 2026-07-30 |
| Board / officer change · Q2 2026 ORIC PHARMACEUTICALS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 18, 2026 • 94,571,281 shares represented at meeting | 2026-06-22 |
| Quarterly report · Q1 2026 ORIC PHARMACEUTICALS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Investments: $419.7 million in total liquid assets (cash $56.4M + short- | 2026-05-04 |
| Results announced · Q2 2026 ORIC PHARMACEUTICALS Q1 2026 SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and investments: $419.7 million as of March 31, 2026 (includes $59.9 | 2026-05-04 |
| Proxy statement · Q2 2026 ORIC PHARMACEUTICALS, INC. – 2026 PROXY SUMMARY CEO COMPENSATION • Jacob M. Chacko, M.D., President and Chief Executive Officer – Total compensation | 2026-04-28 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Oric Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.